Core Insights - Ernexa Therapeutics has developed a novel iMSC-based immunotherapy platform that successfully converts "cold" ovarian tumors into "hot" tumors, potentially enhancing immune response and improving patient outcomes [1][2][4] Company Overview - Ernexa Therapeutics (Nasdaq: ERNA) focuses on innovative cell therapies for advanced cancer and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) to create induced mesenchymal stem cells (iMSCs) [5][6] - The company is currently developing two preclinical cell therapy products: ERNA-101, aimed at activating the immune system against cancer, and ERNA-102, targeting inflammation in autoimmune diseases [6] Research Findings - The study demonstrated that iMSCs engineered to secrete cytokines IL-7 and IL-15 can migrate into the tumor microenvironment, leading to significant immune activation, including T cell and macrophage infiltration [2][3] - In a syngeneic ovarian cancer mouse model, treatment with IL-7/IL-15-secreting iMSCs resulted in a significant reduction in tumor burden and extended survival [3] Upcoming Presentation - Ernexa will present its findings at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025, with a poster titled "Engineering iPSC-derived mesenchymal stem cells (iMSCs) to secrete IL-7/IL-15 for modulation of the tumor microenvironment in a 'cold' ovarian tumor model" [4]

Core Insights - Ernexa Therapeutics has established a new subsidiary, ErnexaTX2, to support the preclinical development of its lead program, ERNA-101, for ovarian cancer and to prepare for clinical activities anticipated in 2026 [1][3]. Company Developments - The formation of ErnexaTX2 demonstrates the company's commitment to the Texas ecosystem and its readiness for clinical manufacturing, regulatory interactions, and site activation in the future [2]. - Ernexa is advancing its infrastructure in anticipation of Investigational New Drug (IND)-enabling activities, with ERNA-101 on track for IND-enabling studies in 2025 and first-in-human studies targeted for 2026 [3]. Product Information - ERNA-101 is designed to activate and regulate the immune system's response to recognize and attack cancer cells, while ERNA-102 targets inflammation to treat autoimmune diseases [5]. - The company's core technology involves engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), providing a scalable, off-the-shelf treatment option [4].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from _________ to _____________ Commission file number: 001-11460 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Ernexa Therapeutics Inc. (Exact name of registrant as specified in its charter) 1035 Cambridge St ...

Core Insights - Ernexa Therapeutics presented new data on engineered cell therapies for ovarian cancer at the AACR Annual Meeting 2025, highlighting the potential of these therapies to enhance immune response and shrink tumors [1][4]. Company Overview - Ernexa Therapeutics (Nasdaq: ERNA) focuses on developing innovative cell therapies for advanced solid tumors and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) transformed into induced mesenchymal stem cells (iMSCs) [5][6]. - The company’s lead product, ERNA-101, aims to activate and regulate the immune system's response against cancer cells, specifically targeting ovarian cancer [6]. Research Findings - The study demonstrated that iMSCs significantly slowed tumor growth and improved survival rates in mice with ovarian cancer, increasing the presence of immune cells such as T cells, natural killer (NK) cells, and macrophages [3]. - iMSCs were shown to enhance T cell growth and multiplication, even in drug-resistant cancer cases, outperforming traditional MSCs in these aspects [3]. Future Implications - The findings suggest that ERNA-101 could represent a more effective, accessible, and scalable treatment option for cancer patients, reinforcing Ernexa's commitment to advancing cancer therapies [4].

CAMBRIDGE, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that new data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. About ErnexaTherapeutics Ernexa Therapeutics (Nasdaq: ERNA) is developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune disease. Ernexa's core technolog ...

Core Insights - Ernexa Therapeutics is advancing its strategic focus on innovative cell therapies for cancer and autoimmune diseases, particularly ovarian cancer [1][2][3] - The company has entered into a securities purchase agreement for a private placement of approximately 69.3 million shares at a price of $0.1046 per share, totaling around $7.25 million, pending stockholder approval [1][2] - The first closing of this transaction occurred on April 2, 2025, raising approximately $1.1 million from the issuance of about 10.4 million shares [2] Company Overview - Ernexa Therapeutics specializes in developing cell therapies targeting advanced solid tumors and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) to create allogeneic synthetic mesenchymal stem cells (iMSCs) [4] - The company is currently focused on two preclinical cell therapy products: ERNA-101, aimed at treating ovarian cancer, and ERNA-102, designed to address inflammation in autoimmune diseases [5] Recent Developments - The recent fundraising follows a previous private investment in public equity (PIPE) round in 2024, which secured $5 million in financing [3] - Ernexa has undergone a rebranding to reflect its new strategic direction, emphasizing its commitment to advancing therapeutic innovation [2][3]

Core Insights - Ernexa Therapeutics has shifted its strategic focus from a cell therapy platform to prioritizing product development, emphasizing its commitment to patient impact with the new tagline "Breaking Through Defenses, Delivering Hope" [1][2] Company Overview - Ernexa Therapeutics, formerly Eterna Therapeutics, is a leader in cell therapies targeting advanced cancer and autoimmune diseases, with a focus on engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs) [1][6] - The company aims to provide scalable, off-the-shelf treatment solutions through its allogeneic synthetic iMSCs, addressing challenges such as immune rejection and donor shortages [2][6] Product Development - Ernexa is developing two cell therapy products currently in preclinical trials: ERNA-101, aimed at enhancing the immune system's response to cancer, and ERNA-102, designed to treat inflammation and autoimmune diseases [3][7] - ERNA-101 is specifically being developed for ovarian cancer, a field with significant unmet medical needs due to the lack of effective targeted therapies [4][5] Market Potential - The company highlights the potential of ERNA-101 and ERNA-102 to significantly impact the treatment landscape for ovarian cancer and autoimmune diseases, respectively [5][7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 1-11460 Eterna Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 31-1103425 (State or O ...

Core Insights - Eterna Therapeutics is advancing its induced mesenchymal stem cell (iMSC) therapy programs for treating advanced solid tumors and autoimmune diseases, with a successful inaugural meeting of its Scientific Advisory Board focusing on preclinical advances and clinical trial roadmaps [1][2][3] Company Overview - Eterna Therapeutics (Nasdaq: ERNA) specializes in innovative cell therapies, particularly through engineering induced pluripotent stem cells (iPSCs) into iMSCs, offering scalable, off-the-shelf treatment solutions without the need for patient-specific cell harvesting [4] Product Development - The company is developing two lead products: ERNA-101, aimed at activating the immune system to target cancer cells, and ERNA-102, designed to address inflammation in autoimmune diseases, with a primary focus on ovarian cancer for ERNA-101 [5][8] Scientific Advisory Board Insights - The Scientific Advisory Board includes leading experts who engaged in discussions about advancing next-generation cell therapies, emphasizing the importance of scientific rigor and innovation [2][7] - Highlights from the meeting included positive preclinical data for ERNA-101, strategies for optimizing dosage and administration routes, and potential combination therapies with CAR-T therapy and other immunomodulatory approaches [8] Future Directions - Eterna plans to continue collaboration with the Scientific Advisory Board and stakeholders to translate innovative therapies into clinical practice, with a focus on rigorous quality, safety, and efficacy criteria [3][8]

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (NASDAQ:ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome Zeldis, M.D., Ph.D., and Blythe Sather, Ph.D., to the company's scientific advisory board. "We are fortunate to welcome Dr. Zeldis and Dr. Sather," said Sanjeev Luther, President & CEO of Eterna Therapeutics. "Their extensive experience in developing transformative, high-profile cell therapies for solid tumors has ...